Nautilus Biotechnology Inc. has announced an agreement with the Allen Institute to explore the connection between tau protein and neurodegenerative conditions, particularly Alzheimer's disease. This collaboration will utilize Nautilus' single-molecule proteomics method, Iterative Mapping, to investigate tau proteoforms. The company's recent preprint, "Development of a method for large-scale single-molecule analysis of tau proteoforms," highlights the platform's capabilities in providing high-resolution biological insights from brain samples of Alzheimer's patients. The study presents initial validation of the method's accuracy, sensitivity, and reproducibility. The results of this collaboration have not yet been presented, as the research is ongoing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.